GLP-1 Agonists: Types, Options & Biomarker-Guided Selection

More than 10 distinct GLP-1 agonist medications are now available or in advanced development, each with different potency, dosing schedules, and mechanisms of action. The FDA-approved options range from short-acting oral formulations to long-acting injectables, with demonstrated efficacy in weight management and cardiometabolic outcomes.

Choosing among GLP-1 agonists requires understanding not only the clinical evidence for each option but also your individual health context and biomarker profile. PlexusDx provides a precision-wellness framework that combines pharmacological knowledge with optional genetic testing to support more personalized conversations with your healthcare provider about which medication may be most suitable.

Current FDA-Approved GLP-1 Agonists and Their Characteristics

Five GLP-1 receptor agonists are currently FDA-approved for weight management: semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda), dulaglutide (Trulicity), and phentermine/topiramate (Qsymia). Each has distinct dosing frequency, onset of action, and maximum therapeutic dose ranges.

Semaglutide is administered weekly via subcutaneous injection or available as an oral formulation (Rybelsus). Tirzepatide, a dual GIP/GLP-1 receptor agonist, is injected weekly and has demonstrated superior weight reduction compared to semaglutide monotherapy in clinical trials. Liraglutide requires daily injections and shows more modest weight loss effects. Understanding these structural and practical differences is essential for informed decision-making.

GLP-1 Agonist Classification: Mechanisms, Efficacy, and Delivery Modalities

GLP-1 agonists are categorized by receptor specificity (GLP-1 only vs. dual GIP/GLP-1), dosing frequency (daily vs. weekly), and delivery route (injectable vs. oral). This classification framework helps patients and providers weigh trade-offs between convenience, tolerability, and demonstrated efficacy in clinical populations.

Genetic Predispositions in Peptide Pathways and Treatment Response Variability

Individual genetic variation in GLP-1 receptor signaling, GIP receptor function, FTO metabolic genes, and melanocortin-4 receptor pathways may influence how different people respond to GLP-1 agonist therapy. These predispositions do not determine medication response but may help provide clinical context for provider discussions.

The Precision Peptide Genetic Test examines key variants in GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 to reveal predispositions in peptide metabolic and appetite-signaling pathways. This biomarker data should be interpreted by a qualified healthcare provider as one input among clinical history, comorbidities, prior medication trials, and current health metrics.

Safety Considerations and Who Should Discuss GLP-1 Agonist Options With a Provider

GLP-1 agonists carry FDA black-box warnings for personal or family history of thyroid cancer or multiple endocrine neoplasia type 2. Common side effects include nausea, vomiting, and gastrointestinal upset, which typically diminish over time. Patients with a history of diabetic retinopathy or severe pancreatitis require careful provider evaluation.

Ideal candidates for GLP-1 agonist therapy typically have a BMI ≥27 with weight-related comorbidities or a BMI ≥30 without comorbidities. However, individual medical history, medication interactions, kidney function, and cardiovascular status must be assessed by a qualified healthcare provider. Genetic biomarker insights can inform this evaluation but do not replace thorough clinical assessment.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that choosing among multiple GLP-1 agonist options requires both evidence-based knowledge and personalized biomarker context. Our Precision Peptide Genetic Test reveals predispositions in four key peptide signaling pathways—GLP-1R, GIPR, FTO, and MC4R—which may help provide context for informed conversations with your healthcare provider about medication selection and potential response patterns.

The genetic test results do not predict exact medication response or guarantee efficacy; instead, they map your individual peptide-pathway predispositions to support a more nuanced clinical discussion. For example, specific FTO or MC4R variants may correlate with metabolic or appetite-regulation patterns that inform which GLP-1 or dual-agonist approach might align with your physiology.

Once you begin treatment with a compounded GLP-1 option through PlexusDx, this biomarker information empowers you and your provider to monitor response, adjust doses with confidence (at no additional cost via our flat-rate pricing model), and consider combination therapies or alternatives if needed. This precision-wellness approach transforms generic GLP-1 selection into a data-informed partnership.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

• Glp Receptor 1 Agonists
• Glp 1 Receptor Agonists For Weight Loss
• Maximus Glp 1
• Found Glp 1